The Norwegian EXercise and Atrial Fibrillation Initiative (NEXAF) is a collaborative project within afib.no addressing research questions related to exercise and atrial fibrillation. The project includes three main work packages:
NEXAF I is a national multicenter randomized controlled trial of a 12-month exercise intervention in atrial fibrillation patients. Specific exercise recommendations do not exist for persons with atrial fibrillation. In this study, 500 patients will be randomized to organized training with close follow-up, or to a control group. The study aims to investigate effects of the exercise intervention on quality of life, symptom burden, cardiovascular risk factors and cardiac function. Read more about the study HERE.
NEXAF II is a randomized controlled trial investigating effects of reduced exercise intensity, and mechanisms for atrial fibrillation in endurance athletes with atrial fibrillation. Despite a lack of knowledge from studies, athletes are often advised to reduce exercise intensity (detraining) after being diagnosed with atrial fibrillation. 120 active non-elite or elite athletes will be randomized to 16 weeks of reduced exercise intensity or to a control group upholding high intensity exercise. The study aims to investigate the effect of detraining on the burden of atrial fibrillation.
NEXAF III is an epidemiological study based on data collected in The HUNT Study, The Tromsø Study and The Birkebeiner Study. The study will investigate long-term effects of physical activity and exercise on mortality, stroke risk and other endpoints among persons with atrial fibrillation.
Project leaders: The Norwegian Exercise and Atrial Fibrillation Initiative is led by Bjarne Martens Nes, K.G. Jebsen Center of Excellent Research Group (CERG), Norwegian University of Science and Technology (NTNU), and Marius Myrstad, Bærum Hospital.
Project leader NEXAF I: Bjarne Martens Nes, CERG, NTNU
Project leader NEXAF II: Marius Myrstad, Bærum Hospital
Project leader NEXAF III: Bente Morseth, The Arctic University of Norway, Tromsø. The study has been funded by Helse Nord
Steering Committee: Bente Morseth (leader), Bjarne Martens Nes, Marius Myrstad, Maja-Lisa Løchen (The Arctic University of Norway, Tromsø), Jan Pål Loennechen (CERG, NTNU), Arnljot Tveit (Bærum Hospital).
Institutions: CERG, NTNU and St. Olavs Hospital, Trondheim, Bærum Hospital, The Arctic University of Norway, Tromsø, Leuven University Hospital, Belgium, Baker Heart and Diabetes Insitiute, Melbourne, Australia.